HomeAI · summaries
Storia in 2 fonti
REGENXBIO Announces Alignment with FDA on Path Forward for NAVSUNLI™ BLA Resubmission for Accelerated Approval; First Potential Gene Therapy for MPS II
REGENXBIO Announces Alignment with FDA on Path Forward for NAVSUNLI™ BLA Resubmission for Accelerated Approval; First Potential Gene Therapy for MPS II
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
REGENXBIO Announces Alignment with FDA on Path Forward for NAVSUNLI™ BLA Resubmission for Accelerated Approval; First Potential Gene…
REGENXBIO Announces Alignment with FDA on Path Forward for NAVSUNLI™ BLA Resubmission for Accelerated Approval; First Potential Gene Therapy for MPS II
- ·
benzinga.com
Regenxbio Gains Fresh Chance As FDA Reconsiders Gene Therapy - Regenxbio (NASDAQ:RGNX)
FDA reverses its rejection of Regenxbio Navsunli, allowing the company to refile its gene therapy application.